Several new therapeutic approaches for the treatment of monoclonal B cell lymphomas are currently being investigated. In parallel with new therapeutic modalities, more sensitive diagnostic methods are needed. These methods should be highly sensitive in detecting very low amounts of malignant cells and should be specific for the malignant clone. In addition, these methods should allow the quantification of residual tumor cells. In this study a new real-time polymerase chain reaction (LightCycler) was evaluated to quantify residual tumor cells in monoclonal B cell malignancies. This technology combines the advantages of rapid cycling PCR with the online detection of PCR products using fluorescent dyes. Our assay is based on immunoglobulin heavy chain (IgVH)-specific PCR with allelespecific primers complementary to hypervariable CDRII and CDRIII regions. A set of framework region III (FRIII)-specific hybridization probes was used for detection of the specific amplification product, and IgVH copy number was quantified with the cloned IgVH sequence as an external standard. The approach was evaluated with the Hodgkin lymphoma cell line L428 in order to quantify L428 dilutions. L428 cells mixed with peripheral blood mononuclear cells (PBMNCs) were detected and quantified with a sensitivity of one cell within 1 × 10 5 PBMNCs. Sample DNA from the peripheral blood and from the bone marrow of two patients with B-CLL was analyzed in the new set up at different time points before and after therapy. Statistically significant changes in IgVH copy numbers were documented in both patients. We conclude that this technology offers an additional opportunity to detect and quantify residual tumor cells in B-CLL over several log steps with a high sensitivity. The kinetics of residual tumor cell counts in B-CLL can be analyzed by this method. Leukemia (2000) 14, 754-766.
Introduction
Since B-CLL has remained an incurable disease with standard treatment, new approaches including high-dose chemotherapy or immunotherapy are being evaluated. 1 Previous studies have shown that a combination of cytotoxic drugs with the monoclonal anti-CD20 antibody IDEC-C2B8 (Rituximab) can induce complete remission (CR) in low-grade follicular lymphoma on the molecular level. 2 This antibody has been shown to induce a fast reduction of tumor cell load in B-CLL, 3, 4 and investigations on the effect of a combination with fludarabine are ongoing in clinical trials.
With the advent of more effective therapeutic modalities, methods to better evaluate and quantify minimal residual disease (MRD) in patients with malignant lymphoma are needed. Immunological staining using monoclonal antibodies and polymerase chain reaction (PCR) are used to detect residual malignant cells in acute and chronic leukemias and lymphomas. At present, the highest sensitivity is reached with PCR allowing the detection of one malignant cell in 10 6 normal cells. 5 The clone-specific hypervariable complementarity determining regions (CDRs) of the immunoglobulin heavy chain locus (IgVH) provide a useful marker for monitoring MRD in B cell lymphoma during and after treatment. 6, 7 Reports on different malignancies support the hypothesis that residual tumor cells may only lead to a relapse once a threshold cell number is reached. 8, 9 As a consequence, several quantitative PCR (qPCR) assays were developed. Different conventional approaches have been described, including measurement of the amount of PCR product, competitive qPCR, co-amplification of target and control genes and limiting dilution qPCR. 10 Recently, several 5Ј exonuclease-based qPCR assays have been developed, which allow a cycle by cycle online documentation of PCR amplification. [11] [12] [13] [14] An additional format for this so called real-time qPCR based on the LightCycler PCR system was recently developed. 15, 16 The LightCycler combines the advantages of real-time qPCR and rapid cycle PCR. It is a closed-tube system requiring no post-PCR manipulation. Normalization genes are available if necessary and the analysis can be performed in the log-phase of reactions, which also allows simultaneous analysis of different genes. With this rapid thermocycler, a complete PCR can be performed within 30 min.
CDRII/CDRIII-specific ASO (allele-specific oligonucleotide) PCR has shown to be highly specific and sensitive. [17] [18] [19] Based on this approach, the aim of our study was to establish a realtime qPCR assay on the LightCycler PCR system. For this purpose, sets of fluorescence marked hybridization probes annealing in the framework region 3 (FRIII) of the IgVH segment were designed, which can be detected by specific hybridization using the LightCycler.
Here, we demonstrate that residual malignant cells in B-CLL can be detected and quantified with this newly developed approach.
Materials and methods

Cell lines
Hodgkin's disease cell line L428 20 was grown in RPMI (10% FCS, 50 g/ml penicillin, 50 g/ml streptolysin).
Patients
Patient CLL-04 (male, born in 1938) was included in an ongoing study for treatment of B-CLL with a combination of fludarabine and Rituximab (Mabthera). B-CLL was diagnosed in October 1996 with Binet stage B. In September 1998, when he was included in our study, the patient's total leukocyte count was 6150/l, with 32.3% lymphocytes, of which 25.6% were B cells. In November 1998, the leukocyte count was 4340/l, with 22% lymphocytes, of which 0.7% were CD19 positive. In January 1999, the leukocyte count was 5210/l, with 10% lymphocytes, of which 1.3% were CD19 positive. The patient was in complete clinical remission (criteria: absence of lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms, normal blood counts, neutrophils Ͼ1.5 × 10 9 /l, platelets Ͼ100 × 10 9 , Hb Ͼ11 g/dl, lymphocytes Ͻ4.0 × 10 9 , bone marrow biopsy with normal cellularity and lymphocytes Ͻ30%). In February 1999 a bone marrow biopsy was obtained, which documented a remission of the B-CLL. In July 1999, the leukocyte count was 4650/l, with 36% lymphocytes of which 41% were B cells.
B-CLL was first diagnosed in patient CLL-05 (male, born in 1932) in May 1994, with Binet stage B. He also was included in the above mentioned study in September 1998, and at this time point the patient's total leukocytes were 106 500/l, with 96.7% lymphocytes, of which 98.5% were CD19 positive. In September 1998 a diffuse infiltration of the bone marrow with small lymphoid cells was reported (80%). In March 1999, the patient had 5600/l total leukocytes, with 26.5% lymphocytes of which 21.5% were CD19 positive. Malignant cells were still documented in FACS analysis. In the bone marrow, the diffuse infiltration with small lymphoid cells was still present (50%).
DNA extraction
EDTA blood and bone marrow aspirates were obtained at the different time points, in every case before therapy and after four cycles of a combined fludarabine/Rituximab treatment, which was finished after 6 months. After separation of mononuclear cells (MNCs) by Ficoll density gradient preparation (Ficoll Hypaque; Pharmacia Biotech, Uppsala, Sweden), whole genomic DNA was extracted following a standard protocol 21 which has previously been used for detection of MRD. 22 The same protocol was used for extraction of DNA from L428 cells.
Sample preparation, PCR setup, and analysis of PCR products was performed in physically separated areas.
Human genomic DNA for negative controls
Peripheral blood mononuclear cells (PBMNCs) of a healthy donor were isolated as described above. To perform an additional specificity control for ASO-PCR setups, B cells were positive selected from MNCs by MACS (CD19 MicroBeads; Miltenyi Biotec, Bergisch-Gladbach, Germany), following the manufacturer's guidelines. The positive selected cells were analyzed for percentage of CD20 positivity by FACS, and genomic DNA was extracted as outlined above.
Amplification, cloning and sequencing of the IgVH
A set of VH consensus primers was used for amplification of IgVH (Table 1 ; Eurogentec, Brussels, Belgium). Primers were described previously. 23 PCR conditions were: 0.2 g genomic DNA, 200 M primers, 200 M dNTPs (containing dUTP instead of dTTP; Perkin Elmer, Norwalk, CT, USA), 1.0 mM MgCl 2 , 2.5 U Taq-Polymerase (Pharmacia) in a 50 l volume. After 5 min at 95°C and a hot start, the following parameters were used: 40 cycles with 1 min 95°C, 1 min 65°C, 2 min 72°C.
The PCR product was directly cloned into pCRII (T/A-cloning kit; Invitrogen, San Diego, CA, USA). Minipreps of positive Leukemia clones were performed (QIAprep Spin Miniprep; Qiagen, Hilden, Germany), positive clones were identified by digestion with EcoRI, five independent positive clones were sequenced with the Big Dye Terminator Ready Reaction Cycle Sequencing Kit on an ABI PRISM Automated Sequencer (Perkin Elmer).
ASO (Allele-Specific Oligonucleotide) PCR
CDRII and CDRIII-specific primers were designed with OLIGO 4.0 (National Biosciences, Plymouth, MN, USA) ( Table 1) . As a positive control PCR, 10 copies of plasmid DNA were diluted into 1 g of genomic DNA extracted from PBLs of a healthy donor. PCR from patient and cell line samples was performed with 1 g genomic DNA as template. 
Generation of plasmid standards for real-time qPCR
A maxi-scale plasmid preparation (QIAgen Plasmid Maxi Kit; Qiagen) of pCRII containing the IgVH sequence from patients CLL-04, -05 and L428 was performed. DNA was resuspended in water, and OD 260 was determined in three independent experiments, the mean OD was calculated, and DNA concentration was estimated according to Sambrook et al. 24 The copy number was calculated from the concentration, mean molecular weight of the nucleotides (660 g/mol) and plasmid length. Plasmid DNA was digested with 1 U of HindIII (RMB) for 1 h at a concentration of 1 × 10 8 copies/l. The enzyme was inactivated at 95°C for 10 min. DNA was diluted into 1.5 ng/ml human genomic DNA (RMB) in log steps down to 1 copy in 2 l volume. For evaluation of standards, limiting dilution assays were performed as suggested by Wang and Spadoro. 25 PCR conditions were chosen as described under ASO-PCR. The theoretical estimation of the copy numbers was in good correlation with the experimentally estimated copy numbers. Standards were aliquoted and stored at −20°C.
Real-time qPCR
Real-time quantitative PCR systems consist of two different instrument components, a cycler and a fluorescence-detection component, which allows a cycle by cycle monitoring of PCR amplification. For this study, the LightCycler System (RMB) was used, which is optimized for two fluorescence formats, the double stranded DNA binding SYBR Green I dye and fluorescence marked hybridization probes (Hyb-probes).
For quantification of genomic IgVH DNA, we designed two hybridization probes which are specific for the FRIII segment of the IgVH sequence from patients CLL-04, -05 and L428 (Table 1 ; TIB Molbiol, Berlin, Germany). The melting tempera- ture (Tm) of the probes is approximately 10°C higher than the Tm of the primers used in PCR (calculation of Tm after the thermodynamic method 26 ). Probes 3FL are marked with fluorescein at its 3Ј terminus, probes 5LC are marked with LightCycler Red 640 at its 5Ј terminus. After binding to FRIII, both probes are separated by only one nucleotide. A schematic illustration of a CDRII/CDRIII-specific ASO-PCR and an ASO-PCR with hybridization probes is demonstrated in Figure 1 .
Quantification of IgVH copy number is based on a set of seven external standards, containing 1 to 1 × 10 6 plasmid copies. PCR with these standards was performed in the presence of 1 g genomic DNA extracted from PBLs of a healthy donor. DNA master mix (RMB) containing Taq-Polymerase, dNTPs (containing dUTP) and PCR buffer and 1 U UNG (RMB). Values for MgCl 2 , Hyb-probe concentration, primer concentration and program parameters for the three different systems are documented in Table 2 . A hot start was performed with the TaqStart antibody (Clontech, Palo Alto, CA, USA). After incubation of 0.29 g TaqStart antibody per 2 l of LightCycler DNA master mix at room temperature (RT) for 5 min, the reagents were supplemented. PCR conditions for patient samples were identical to conditions for standards. One g genomic DNA of each patient sample was analyzed in 20 l. To decontaminate PCR reactions with UNG, they were incubated at RT for 10 min before starting PCR. As temperature transition rate 20°C/s was chosen.
PCR reactions were run in glass capillaries on the Light Cycler amplification and detection system with Run32 software, run data were analyzed with the quantification program Quant V2.7 and V3.0 (RMB). The background subtraction function was used to normalize background fluorescence between different samples allowing definition of a noise band. A log-line was generated with three points of the logarithmic phase of PCR reaction. Crossing points of the log-line with the noise band are plotted against log concentration of the standards to generate a standard curve. The level of the noise band was corrected when the mean squared error of the standard curve was greater than 1 × 10 −1 . LightCycler's data analysis software extrapolates sample concentration with their crossing points from the standard curve. All samples were analyzed in three or more parallels. Mean concentration (MV), standard deviation (SD) and coefficient of variation (CV) were calculated.
Statistical analysis
Statistical analysis was performed to check whether the estimated copy numbers in patient samples were significantly different. Tests for independent samples were used and the significance was calculated with either the KolmogorovSmirnov test, or the t-test. These tests are suitable for small numbers of spot checks. The samples do not need to be normally distributed.
Results
Amplification of tumor IgVH genes with consensus PCR
With primers VH5 and JH1, 2, 4, 5 for L428, VH1 and JH6 for CLL-04 and VH3 and JH6 for CLL-05 specific products of 340 bp were amplified. Other primer combinations amplified either a smear or unspecific bands, suggesting that they were not specific for tumor IgVH recombination (data not shown). PCR product was cloned into pCRII, miniprep DNA of five positive clones was sequenced containing an identical IgVH sequence. A sequence alignment with DNAPLOT (http:///www.genetik.uni-koeln.de/dnaplot) showed that CLL-04-IgVH belongs to the VH1 family, CLL-05-IgVH belongs to the VH3 family, and L428-IgVH belongs to the VH5 family. All rearrangements were in frame, sequences are shown in Table 3 .
Design and evaluation of ASO-PCR
Sets of primers specific for the CDRII and CDRIII region of IgVH were designed (Table 1) . CLL-05/5Ј binds in FRII and CDRII, because an optimal Tm and G/C content could not be obtained when the primer covered CDRII only. CDRII ASO primers for CLL-04 and L428 hybridize inside the CDRII region. According to OLIGO4.0, the primer pairs should not form secondary structures. The designed primersets were tested for sensitivity and specificity. Specific PCR products of 189 bp for CLL-05, 196 bp for CLL-04 and 143 bp for L428 were detected only with genomic DNA from the corresponding samples (blood, bone marrow and cell line L428), not from genomic DNA from PBMNCs. One to 10 copies of plasmid DNA containing CLL-05 IgVH were detected in 1 g genomic DNA isolated from MNCs of a healthy donor (data not shown). This corresponds to a sensitivity of 1 tumor cell in 1.6 × 10 5 cells, with one human genomic equivalent corresponding to 6 pg of genomic DNA 27 and one IgVH target per tumor cell.
As an additional control for specificity of the clonotypic primers, we performed an ASO-PCR with genomic DNA isolated Leukemia from a polyclonal B cell population, which was positively selected from mononuclear cells by CD19 MACS. After positive selection, FACS analysis documented 61.95% CD20-positive cells (data not shown). ASO-PCR for L428, CLL-04 and CLL-05 was negative with this template. The result of this negative control is shown in Figure 4 for one patient CLL-05. The corresponding tests for L428 and CLL-04 were also negative (data not shown).
Principles of real-time quantification with the LightCycler
The LightCycler technology is based on a rapid thermal cycler, which works with a transfer of hot and/or cool air to the sample chamber for temperature control. PCR probes are run in glass capillaries with a high surface-to-volume ratio enabling temperature transition rates up to 20°C/s. Thus, PCR reactions with 40 to 60 cycles can be performed in 30 min. An integrated optical unit contains a light-emitting diode (LED) and three detection channels. Several fluorescent dyes and formats are available which can be used for online detection of PCR products (for technical details see Refs 15, 16) .
Fluorescence-labeled hybridization probes (Hyb-Probes) which provide maximum specificity were used for product identification. For this approach two different Hyb-Probes (probes A and B) must be designed, which bind to a region in the middle of the amplification product in a head-to-tail arrangement. Probe A is marked with an acceptor fluorophore (LightCycler-Red 640) at its 5Ј end, probe B is marked with a donor fluorophore (fluorescein) at its 3Ј end (Figure 1 ). The dyes on the probes are approximated by hybridization, and if fluorescein is excited and emits green fluorescent light at a slightly longer wavelength, the emitted energy excites LightCycler-Red 640 to emit red fluorescent light at an even longer wavelength. This effect is called fluorescence resonance energy transfer (FRET). 28 The intensity of the FRET-generated longer wavelength is proportional to the amount of specific PCR products in the reaction vessel. As FRET only occurs when both Hyb-probes are binding to the DNA, fluorescence is measured at the end of the annealing step. For our assay we designed Hyb-probes specific for the FRIII of IgVH ( Figure  1 ). PCR reactions and quantification procedures are described in detail in the Methods section.
Generation of a standard curve for quantification of IgVH copy number
Absolute quantification of DNA copy number is based on the generation of a standard curve with external standards. The standards are run in parallel with the probe under identical PCR conditions. Standards from 1 to 1 × 10 6 copies of a plasmid containing the patients IgVH insert were used for quantification of patient samples. This range was chosen as the maximal and minimal tumor cell counts theoretically contained in 1 g of genomic DNA (1.66 × 10 5 copies, with 6 pg DNA corresponding to one genomic equivalent). Fluorescence curves of standards for one patient (CLL-05) are shown in Figure 2 . Four tubes containing one copy were run in parallel, since PCR with high dilutions follows a Poisson distribution. This is based on the fact that a tube might contain one copy or no copy resulting in a PCR which is not positive in every case. 25 Consequently, only one out of four tubes gave a positive result. The log-lines, corresponding to the log linear Table 3 Nucleotide sequence of the immunoglobulin heavy chain variable region genes verified in this study range of the PCR reaction are shown in Figure 3 . A noise band for fluorescence values was defined, the crossing points were calculated, and a standard curve was generated as described above. An error of 3.65 × 10 −3 was calculated for this standard curve, which was a good basis for further quantification.
Samples from patients and cell lines were analyzed with 1 g of genomic DNA per reaction. One g of genomic DNA from MNCs of a healthy individual was added to the standard reactions to achieve identical reaction conditions between standards and samples. This was necessary because different copy numbers were quantified when standards without 1 g human genomic background DNA were analyzed (data not shown).
Results of amplification of the standards were verified on a 1% agarose gel. Figure 4 shows the results from patient CLL-05. No unspecific amplification product was documented.
Cells containing rearranged IgVH genes can be quantified using plasmid DNA containing the IgVH segment as external standard
One major question using the real-time quantitative PCR technique is whether the estimated number of copies compared with the external plasmid standard corresponds to the true cell number from which DNA was extracted. To answer this question, we performed quantification experiments with the Hodgkin lymphoma cell line L428 containing a rearranged IgVH sequence.
L428 cells were adjusted to a concentration of 1 × 10 5 /l by repeatedly counting cells in a hemocytometer chamber and resuspending them in an appropriate volume of 0.9% NaCl. Cells were diluted in log steps, ranging from 1 × 10 4 to 10 cells per 0.5 ml Eppendorf tube. After centrifugation (10 min, 15 000 g), cells were resuspended in 10 l PCR direct lysis buffer containing proteinase K. 20 The complete 10 l volume was used for the quantification experiment. Five independent experiments were performed for each dilution step. All experiments were run in three parallel reactions. Mean values (MV) and standard deviations (SD) are shown in Table 4 . The MV for the 1 × 
Dilutions of L428 cells within mononuclear cells of the peripheral blood can be detected with a high sensitivity and can be quantified within a background of negative cells
We performed experiments with L428 cells diluted into mononuclear cells of the peripheral blood. Dilutions of 0.01% (1:10 4 ), 0.001% (1:10 5 ) and 0.0001% (1:10 6 ) L428 cells were produced in a total cell number of 5 × 10 6 cells. Total genomic DNA was extracted, DNA concentration was measured, and quantification was performed as outlined above. Results of three experiments are documented in Table 5 .
In 1 g of the 0.01% dilution we quantified 0.82 × 10 2 (+/− 2.6 × 10 3) copies were measured resulting in an overall mean value of 38 copies. In both dilutions the quantified L428 cell numbers are in good correlation to the theoretical cell numbers. The 1:10 dilution step of L428 in the mixtures from 0.01% to 0.001% L428 cells is well documented with the LightCycler quantification data.
At the 0.001% dilution 9 out of 20 reactions did not give a positive result. All reactions with 0.0001% L428 cells within PBMNCs were negative. Thus the highest sensitivity was reached with the 0.001% (1:10 5 ) dilution. The CV values are in a range comparable to the CV values from Table 4 , which shows the quantification data of L428 cells alone.
Quantification of IgVH copy number in patient samples shows a reduction in tumor cell burden during therapy
Samples from patient CLL-05 were analyzed in parallel with standards. IgVH copy number was calculated by interpolation of the standard curve as described above. Generation of a standard curve. (a) Documents the log-lines of the standard curves from Figure 2 . Fluorescence intensity in logarithmic scales is plotted against the cycle number. Three points of the log-linear phase were used to generate a log-line. To minimize extrapolation errors, the log-lines are extrapolated to the noise band line which defines the beginning of the log linear phase. The intersection of the logline with the noise band is called crossing point (CT). In (b) the calculated CTs are plotted against the common logarithm of standard copy number. The mean squared error of the standard curve is shown.
In a first experiment (17-5-1) the copy numbers of all four samples (PBL 9/98, PBL 3/99, KM 9/98, KM 3/99) were estimated in three parallel reactions. Mean values (MV), standard deviations and coefficients of variation were calculated (Table  6 ). This experiment was repeated (19-5-1) , to proof reproducibility and because CV was above 20% for one sample (PBL 3/99, 24.53%). CV for PBL 3/99 then was slightly better (23.87%), but still exceeding 20%, and CV of KM 3/99 was even worse (43.49%). Quantification of these two samples was repeated using more parallel reactions, which allowed exclusion of curves showing a poor log-linear phase over 3 points. Thus, an intra-assay CV Ͻ20% for both samples was obtained: 18% for PBL 3/99 in (2-6-1) and 18.8% in KM 3/99 in (4-6-02).
Statistical analyses were performed to document differences in the estimated copy numbers before and after therapy. The Kolmogorov-Smirnov test showed that the difference in IgVH copy number in samples PBL 9/98 and PBL 3/99 is highly significant (P Ͻ 0.0001), and also significant for samples KM 9/98 and 3/99 (P = 0.003). Mean values of copy numbers from all experiments outlined in Table 6 are demonstrated in Figure 5 .
Samples from patient CLL-04 were analyzed following the same scheme as for patient CLL-05. For this patient only samples from the peripheral blood were analyzed. Mean values and standard deviations of all measured copy number of samples 9/98, 11/98, 1/99 and 7/99 of patient CLL-04 are documented in Figure 6 . In 9/98, 2.9 × 10 3 (+/−2.2 × 10 3 ) copies were measured. A reduction to 4.9 × 10 1 (+/− 7) copies in samples (11/98, and to 10 (+/− 7) copies in 1/99 was documented. In July 1999 we were able to measure an increase in tumor cell copy number to 2.9 × 10 3 (+/− 1.8 × 10 3 ) copies. From September 1998 to November 1998 a reduction of tumor cells over three log-steps was documented, which was also statistically significant (P = 0.02; t-test for independent samples). Changes from September 1998 to January 1999 (P = 0.708) were not statistically significant, and changes from January 1999 to July 1999 showed a tendency to significance (P = 0.085). For each dilution five independent experiments were performed. Three different dilutions containing 0.01%, 0.001% and 0.0001% were quantified in three independent experiments.
Leukemia
Correlation of LightCycler real-time quantification data with clinical data of the patients
In our quantification experiments, we measured IgVH copy number per 1 g genomic DNA. This corresponds to the tumor cell number per 1.66 × 10 5 normal cells (with 1 genomic equivalent corresponding to 6 pg genomic DNA). This allows calculation of the percentage of tumor B lymphocytes contained within the total leukocyte count.
In the peripheral blood of patient CLL-04 we documented a reduction from 17% tumor cells in September 1998 to 0.03% in November 1998 and 0.006% in January 1999. In July 1999 tumor cells increased to 1.7%. The percentage of B lymphocytes is shown in Table 7 . During the course of therapy, the patient's B lymphocytes were reduced dramatically. Unfortunately the percentage of B-CLL cells has not been quantified in the blood of this patient by FACS, but CD5-positive cells were detectable at every time point. Following clinical criteria the patient reached a clinical remission in February 1999.
In the peripheral blood of patient CLL-05 we were able to document a reduction of B-CLL cells from 1.24% in September 1998 to 0.1% in March 1999. The FACS data documented a reduction of B lymphocytes from 95% to 5.6%, but CD5 remained strongly positive on the B cells. So this patient still had B-CLL cells in the peripheral blood detectable by FACS. The patient's bone marrow showed a percentage of lymphatic cells of 80% in September 1998, and 50% in March 1999. In the quantitative PCR we documented a reduction from 3% tumor cells (5078 within 1.6 × 10 5 normal cells) to 1.5% tumor cells in the peripheral blood.
A direct comparison of real-time PCR quantification data and FACS quantification data was not possible in these two patients, because B-CLL cells were not quantified by FACS, and samples for FACS and samples for LightCycler analysis were not obtained at the same day, but usually within 1 week. As lymphocyte counts change from day to day when patients receive Rituximab, 3 samples obtained at different days cannot be compared with respect to quantity.
Discussion
In this study, the LightCycler format was used to develop a new PCR-based method for quantification of malignant lymphoma cells. This assay was evaluated in a cell line model system and in two patients with B-CLL. The following findings Leukemia emerge from this study: (1) IgVH-specific CDRII and CDRIII region primers and framework region III-specific hybridization probes were designed to detect malignant cells. The use of online detection of PCR products for quantification of malignant cells has been described earlier in a different setup. 29 It was demonstrated that this technique represents
Figure 5
Comparative analysis of IgVH copy number generated from the peripheral blood (PBL 9/98, PBL 3/99) and the bone marrow (KM 9/98, KM 3/99) of patient CLL-05. Mean copy numbers and standard deviations from all experiments are shown. A decrease in absolute IgVH copy number is evident for both, samples from the peripheral blood (PBL 9/98 and PBL 3/99) and the bone marrow (KM 9/98 and KM 3/99) before and after therapy.
Figure 6
Changes in IgVH copy number in the peripheral blood (Sep-9/98, Nov-98, Jan-99, Jul-99) from patient CLL-04. Mean copy numbers and standard deviations from all experiments are shown. A decrease during the course of therapy (Nov-98, Jan-99) and an increase after therapy (Jul-99) can be observed.
Table 7
Comparison of real-time quantification data with flow cytometry data a valuable tool for the detection and quantification of minimal residual disease in B cell malignancies. 12, 14 The aim of the present study was to investigate a new real-time detection format with fluorescent-labeled Hyb-probes available for the LightCycler PCR system.
The method is based on the clone-specific immunoglobulin CDRII/CDRIII ASO-PCR, which was introduced by Corradini et al. [17] [18] [19] This assay has a sensitivity of 1 tumor cell in 1.66 × 10 5 cells in our hands, which can be further increased to 1 tumor cell in 1 × 10 6 cells when six reactions are performed in parallel. This sensitivity is in good correlation with current standards. 5, 30 In this study, the main argument for the use of CDRII and CDRIII-specific primers was to generate a longer segment allowing the design of specific Hyb-probes. With the help of these Hyb-probes we were able to detect and quantify IgVH segments in a real-time qPCR, based on the LightCycler detection format. Since this method seems to be reliable and easy to perform, degenerated Hyb-probes might be designed which can be used for all patients with the same IgVH family. This would dramatically reduce costs for oligonucleotides, as only the additional two specific CDR primers would have to be designed for each patient.
Quantification data obtained with the cloned IgVH segment as an external standard correspond to the true cell number from which genomic DNA has been extracted and which has been analyzed in a real-time qPCR assay. We extracted DNA from dilutions of L428 cells and quantified the IgVH copy number with a L428-specific ASO-PCR. The quantified mean values were in good correlation with the cell number used for DNA extraction and qPCR. With higher dilution we observed an increased error, which is reflected in an increasing CV. These increasing CV values are probably due to the dilution error. According to the manufacturer, CV values for real-time PCR on the LightCycler depend on the copy number. For copy numbers from 10 2 to 10 3 the CVs can be well below 10% (s.d. for C T approximately 0.1), but this number will increase partly because of particle distribution statistics from 25% to 100% in the 10 1 to 10 2 copy range (s.d. for C T approximately 0.6) (data not shown). We also observed this phenomenon in our quantification data obtained from different cell lines and patient samples. Thus, the quantification data obtained with an external standard reflect a true cell number in the sample from which DNA was extracted.
We first determined the sensitivity of our CDRII/CDRIII-specific ASO-PCR by plasmid DNA diluted into 1 g genomic DNA of a healthy donor. This corresponds to a sensitivity of 1 tumor cell within 1.66 × 10 5 normal cells. In order to show that the best sensitivity reached with plasmid DNA as an external standard corresponds to the detection of target cells within a background of negative cells, we quantified the number of L428 Hodgkin cells diluted into PBMNCs of a healthy donor. We were able to quantify L428 cells in dilutions containing as few as 0.001% L428 cells, and the quantification data corresponded to the theoretical cell numbers. At higher dilutions (0.0001% L428 cells), no positive PCR reaction was observed. This indicates that as few as 1 cell within 1 × 10 5 normal cells can be detected with the LightCycler format. This is similar to the sensitivity described for the CDRII/CDRIII ASO-PCR approach. [17] [18] [19] We evaluated the new quantification approach termed LC-ASO-PCR (LightCycler-ASO-PCR) in two patients with B-CLL. In both patients, statistically significant changes in tumor cell load during the course of therapy were documented ( Figures  5 and 6 ). The tendency of changes in the B lymphocyte counts measured by FACS and changes of tumor cell counts measured with the LightCycler were similar (Table 7) . A direct comparison of our FACS data with our real-time PCR data was not possible. It remains to be analyzed if the number of IgVH copies of the patient's tumor clone in genomic DNA extracted from the patient's blood corresponds to his true number of tumor cells in the blood.
Molecular remission in patients with CLL has only been described for treatment protocols using high-dose chemotherapy followed by stem cell transplantation. 7, 31 Important additional information related to the residual tumor cell load of CLL patients can now be documented with this new method by assessing the changes in tumor copy number during the course of therapy. Recent studies demonstrated the therapeutic value of a threshold tumor cell number in different malignancies. 8, 9 Whether a threshold level of remaining malignant cells is a predictive parameter in CLL remains unclear.
Two different groups have recently described the use of real-time technology for quantitative analysis of residual disease in B cell malignancies.
12,14 Gerard et al 12 described a method using a CDRIII-specific oligonucleotide as back primer and an oligonucleotide annealing in the immunoglobulin heavy chain (IgVH) joining region as for primer. Detection of amplification product in this ASO-PCR is based on binding of a fluorescence probe in the CDRIII region. Quantification is performed by comparison of patient probes with standard curves obtained from dilution of plasmid DNA. These authors demonstrated that sensitivity of diluted plasmid DNA standards is identical to the sensitivity observed using diluted genomic DNA as external standard. Pongers-Willemse et al 14 used a fluorescence probe specific for the junctional region of tumor IgVH and designed appropriate VH consensus primer for each probe. Quantification in this setup was performed with limiting dilution. The sensitivity was comparable to the radioactive dot-blot method but inferior compared to liquid hybridization. The use of real-time technology for limiting dilution assays does not cover all possibilities which are inherent in this new and powerful technology. Plasmid DNA as an external standard has several advantages as suggested by Gerard et al. 12 It allows an accurate and absolute quantification of tumor DNA copy number corresponding to tumor cell number as shown in this study. If the same set of standards (aliquoted and stored at −20°C) is used at different time points during follow-up, comparable results can be obtained.
In this study, CVs Ͻ20% for copy numbers in the patient samples were obtained, when appropriate numbers of reactions were analyzed in parallel. CVs are usually calculated for cycle thresholds (C T ) in exonuclease-based real-time qPCR assays. As the calculation of the crossing points for the Light-
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Cycler differs from calculation of C T s in exonuclease-based assays, the CVs from the literature cannot be compared directly. In exonuclease-based assays s.d. for C T values range from 0.07 to 0.24. 29, 32 For one assay the correlation between s.d. of C T and variation of starting quantity was calculated to be 15% variation per 0.2 s.d. 32 Thus, a C T s.d. of 0.24 would result in a CV of 18% which corresponds to the CVs obtained in the quantification experiments described in this study. Unfortunately, a direct comparison between the different realtime quantification systems has not been performed as yet.
Based on our practical experience, this technology could potentially be used routinely although this method is time intensive and requires new primers to be designed for each individual patient. Other groups have documented satisfying results with the CDRII/CDRIII-ASO-PCR. [17] [18] [19] In the PCR systems described in this study, the parameters are within the same range, which is probably due to the similar criteria we used for primer design.
In conclusion, we demonstrate that this real-time qPCR technology provides a powerful new tool for quantification of MRD in B-CLL. This technology might be applicable to a variety of monoclonal B cell lymphomas.
